---
schema_version: "secwatch.filing_event.v1"
accession: "0001077183-25-000005"
form_type: "8-K"
ticker: "NEO"
cik: "0001077183"
company_name: "NEOGENOMICS INC"
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T04:26:45.918222+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeoGenomics CEO Chris Smith to retire April 1; board member Tony Zook named successor

## Summary
- Chris Smith retires as CEO effective April 1, 2025; will serve as special advisor through Feb 2027 at $23,913/month.
- Tony Zook, independent board member since June 2023, appointed CEO effective April 1; base salary $850k with 100% target bonus and ~$8M annual equity target.
- Smith's retirement package includes pro-rated 2025 bonus, accelerated vesting of 265,452 restricted shares, and 12-month option exercise extension.
- Company reaffirms FY2024 guidance: revenue $655–$667M, net loss $(81)–$(78)M, adjusted EBITDA $37–$40M.
- NeoGenomics reported eight consecutive quarters of double-digit revenue growth under Smith's tenure.

## SEC filing metadata
- accession: 0001077183-25-000005
- form_type: 8-K
- ticker: NEO
- cik: 0001077183
- company_name: NEOGENOMICS INC
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1077183/000107718325000005/0001077183-25-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1077183/000107718325000005/neo-20250103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001077183-25-000005
- JSON: https://secwatch.observer/filing/0001077183-25-000005.json
- Plain text: https://secwatch.observer/filing/0001077183-25-000005.txt

## Key facts
- Executive change
  Christopher Smith was appointed as special advisor at NEOGENOMICS INC.
  - Action: appointed
  - Role: special advisor
  source text: The Special Advisor Agreement provides that Mr. Smith will serve as a special advisor to the Company’s Chief Executive Officer until February 26, 2027 in exchange for a fee of $23,913 per month.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718325000005/0001077183-25-000005-index.htm
- Executive change
  Christopher Smith departed as Chief Executive Officer at NEOGENOMICS INC.
  - Action: retire
  - Role: Chief Executive Officer
  source text: Christopher Smith, the Company’s Chief Executive Officer and a member of the Company’s board of directors (the “Board”), will retire effective April 1, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718325000005/0001077183-25-000005-index.htm
- Executive change
  Christopher Smith departed as member of the board of directors at NEOGENOMICS INC.
  - Action: retire
  - Role: member of the board of directors
  source text: Christopher Smith, the Company’s Chief Executive Officer and a member of the Company’s board of directors (the “Board”), will retire effective April 1, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718325000005/0001077183-25-000005-index.htm
- Executive change
  Tony Zook was appointed as Chief Executive Officer at NEOGENOMICS INC.
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On January 10, 2025, the Company announced the appointment of Tony Zook to replace Mr. Smith as Chief Executive Officer effective April 1, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718325000005/0001077183-25-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.